Effects of Qishen Yiqi Dripping Pills (芪参益气滴丸) in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study

Gui-xin He; Jun Xie; Hao Jiang; Wei Tan; Biao Xu

doi:10.1007/s11655-017-2955-1

Your Location：

Home >

Browse articles >

Effects of Qishen Yiqi Dripping Pills (芪参益气滴丸) in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study

Updated：2021-08-27

- Effects of Qishen Yiqi Dripping Pills (芪参益气滴丸) in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study
- Chinese Journal of Integrative Medicine Vol. 24, Issue 3, Pages: 193-199(2018)
- Affiliations：
  
  1. Department of Cardiology, Drum Tower Hospital, Medical School of Nanjing University,Nanjing,China
  2. Department of Cardiology, the First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-017-2955-1
  CLC：
- Published：2018，
  
  Published Online：3 May 2017，
Scan for full text
He, Gx., Xie, J., Jiang, H. et al. Effects of Qishen Yiqi Dripping Pills (芪参益气滴丸) in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study., Chin. J. Integr. Med. 24, 193–199 (2018). https://doi.org/10.1007/s11655-017-2955-1

Gui-xin He, Jun Xie, Hao Jiang, et al. Effects of Qishen Yiqi Dripping Pills (芪参益气滴丸) in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study. [J]. Chinese Journal of Integrative Medicine 24(3):193-199(2018)
He, Gx., Xie, J., Jiang, H. et al. Effects of Qishen Yiqi Dripping Pills (芪参益气滴丸) in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study., Chin. J. Integr. Med. 24, 193–199 (2018). https://doi.org/10.1007/s11655-017-2955-1 DOI：

Gui-xin He, Jun Xie, Hao Jiang, et al. Effects of Qishen Yiqi Dripping Pills (芪参益气滴丸) in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study. [J]. Chinese Journal of Integrative Medicine 24(3):193-199(2018) DOI： 10.1007/s11655-017-2955-1.

摘要

To evaluate the effect of treatment with Qishen Yiqi Dripping Pills (芪参益气滴丸

QSYQ) on myocardial injury and myocardial microvascular function in patients undergoing elective percutaneous coronary intervention (PCI). Eighty patients undergoing elective PCI were randomly assigned to QSYQ and control groups. The QSYQ group received QSYQ at a dosage of 0.5 g 3 times daily (3–7 days before PCI and then daily for 1 month) and regular medication

which comprised of aspirin

clopidogrel

statin

β-blocker

and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker in the absence of contradiction. The control group received only the regular medication. The index of microcirculatory resistance (IMR) was measured at maximal hyperemia after PCI. The fractional flow reserve was measured before and after the procedure. Troponin I levels were obtained at baseline and 20–24 h after the procedure. Pre-PCI troponin I levels between the two groups were similar (0.028±0.05 vs. 0.022±0.04 ng/mL

P=0.55). However

post- PCI troponin I levels in the QSYQ group were significantly lower than that in the control group (0.11±0.02 vs. 0.16±0.09 ng/mL

P<0.01). IMR values were significantly lower in the QSYQ group as compared to the control group (16.5±6.1 vs. 31.2±16.0

P<0.01). Multivariate analysis identified QSYQ treatment as the only independent protective factor against IMR >32 (odds ratio=0.29

95% confidence interval: 0.11–0.74

P=0.01). The present study demonstrated the benefit of QSYQ in reducing myocardial injury and preserving microvascular function during elective PCI.

Abstract

To evaluate the effect of treatment with Qishen Yiqi Dripping Pills (芪参益气滴丸

which comprised of aspirin

clopidogrel

statin

β-blocker

P=0.55). However

post- PCI troponin I levels in the QSYQ group were significantly lower than that in the control group (0.11±0.02 vs. 0.16±0.09 ng/mL

P<0.01). IMR values were significantly lower in the QSYQ group as compared to the control group (16.5±6.1 vs. 31.2±16.0

P<0.01). Multivariate analysis identified QSYQ treatment as the only independent protective factor against IMR >32 (odds ratio=0.29

95% confidence interval: 0.11–0.74

P=0.01). The present study demonstrated the benefit of QSYQ in reducing myocardial injury and preserving microvascular function during elective PCI.

关键词

Myocardial Injurymicrovascular impairmentPercutaneous Coronary InterventionChinese Medicineherbs

Keywords

Myocardial Injurymicrovascular impairmentPercutaneous Coronary InterventionChinese Medicineherbs

references

Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005;111:1027–1032.

Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241–251.

Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528–1536.

Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104:642–647.

Saucedo JF, Mehran R, Dangas G, Hong MK, Lansky A, Kent KM, et al. Long-term clinical events following creatine kinase—myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000;35:1134–1141.

Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatinekinase-MB elevation. Circulation 2001;103:2780–2783.

Aarnoudse W, Fearon WF, Manoharan G, Geven M, van de Vosse F, Rutten M, et al. Epicardial stenosis severity does not affect minimal microcirculatory resistance. Circulation 2004;110:2137–2142.

Ng MK, Yeung AC, Fearon WF. Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation 2006;113:2054–2061.

Fearon WF, Balsam LB, Farouque HM, Caffarelli AD, Robbins RC, Fitzgerald PJ, et al. Novel index for invasively assessing the coronary microcirculation. Circulation 2003;107:3129–3132.

Du WX, Zhu MD, Feng LM, Song QG, Wei Y, Ma P, et al. Intervention effect of Qishen Yiqi Gutta Pills on early ventricular remodeling after acute myocardial infarction. Chin J Evid Based Cardiovasc Med (Chin) 2008;1:41–43.

Zhu MD, Du WX, Liu CY, Zhang JP, Feng LM, Wei Y, et al. Dynamic observation of Qishen Yiqi Gutta Pills on the myocardial inflammatory factors expression in acute myocardial infarction rats. Lishizhen Med Mater Med Res (Chin) 2013;24:22–25.

Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol 2012;60:e44–e164.

Zheng XY, ed. Guiding principle of clinical research on new drugs of traditional Chinese medicine. Beijing: China Medic-Pharmaceutical Sciences and Technology Publishing House; 2002.

Fujii K, Kawasaki D, Oka K, Akahori H, Iwasaku T, Fukunaga M, et al. The impact of pravastatin pre-treatment on periprocedural microcirculatory damage in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2011;4:513–520.

Pijls NH, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 1993;87:1354–1367.

Barbato E, Aarnoudse W, Aengevaeren WR, Werner G, Klauss V, Bojara W, et al. Validation of coronary flow reserve measurements by thermodilution in clinical practice. Eur Heart J 2004;25:219–223.

Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2008;51:560–565.

Cuisset T, Hamilos M, Melikian N, Wyffels E, Sarma J, Sarno G, et al. Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation. J Am Coll Cardiol 2008;51:1060–1065.

Prati F, Pawlowski T, Gil R, Labellarte A, Gziut A, Caradonna E, et al. Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: a major role of plaque embolization? A serial intravascular ultrasound study. Circulation 2003;107:2320–2325.

Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674–678.

Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822–1828.

Lin SQ, Wei XH, Huang P, Liu YY, Zhao N, Li Q, et al. Qishen Yiqi Pills prevents cardiac ischemia-reperfusion injury via energy modulation. Int J Cardiol 2013;168:967–974.

Hong C, Wang Y, Lou J, Liu Q, Qu H, Cheng Y. Analysis of myocardial proteomic alteration after Qishenyiqi Formula treatment in acute infarcted rat hearts. J Chin Mater Med (Chin) 2009;34:1018–1021.

Yan FF, Liu Y, Liu YF, Zhao YX. Effects of Qishen Yiqi Droplet on high sensitivity C reactive protein in experimental atherosclerosis rabbits. Shanghai J Tradit Chin Med (Chin) 2007;41:59–60.

Yan FF, Liu Y, Liu YF, Zhao YX. Effect of Qishen Yiqi Dripping Pills on histology of experimental atherosclerotic plaque. J Nanjing Univ Tradit Chin Med (Chin) 2007;23:295–297.

Yang L, Mao BY. Protection of Qisheng Yiqi Pills on rats with myocardial infarction. Chin J Exp Tradit Med Form (Chin) 2012;18:167–172.

Zhang L, Wang Y, Yu LY, Liu L, Qu H, Wang Y, et al. Qishen Yiqi accelerates angiogenesis after myocardial infarction in rats. Int J Cardiol 2010;143:105–109.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Combined therapy with Chinese medicine and percutaneous transradial coronary intervention for a centenarian patient with acute myocardial infarction

Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial

Effect of Danlou Tablet (丹蒌片) on peri-procedural myocardial injury among patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndrome: A study protocol of a multicenter, randomized, controlled trial

Effect of Shenzhu Guanxin Recipe (参术冠心方) on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Related Author

No data

Related Institution

Heart Center, Guangdong Provincial Hospital of Chinese Medicine

Institute of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Gastroenterology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

The Second Clinical Medical College, Guangzhou University of Chinese Medicine

Guangdong Provincial Hospital of Traditional Chinese medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰